Table 3.
Pathway analysis of biomarkers that distinguish 14 class compounds
| Ingenuity canonical pathways | -log (p-value) | Ratio | Molecules |
|---|---|---|---|
| Mitotic roles of polo-like kinase |
11.6 |
1.45E-01 |
KIF23, CCNB1, ESPL1, CDC20, PTTG1, PRC1, CCNB2, PLK1, CDC2 |
| Cell Cycle: G2/M DNA damage checkpoint regulation |
6.17 |
1.16E-01 |
CCNB1, TOP2A, CCNB2, PLK1, CDC2 |
| ATM signaling |
4.16 |
7.55E-02 |
RAD51, CCNB1, CCNB2, CDC2 |
| Nicotinate and nicotinamide metabolism |
3.03 |
2.94E-02 |
NEK2, PLK1, TTK, CDC2 |
| Inositol phosphate metabolism |
2.57 |
2.27E-02 |
NEK2, PLK1, TTK, CDC2 |
| Sonic hedgehog signaling |
2.15 |
6.06E-02 |
CCNB1, CDC2 |
| Pancreatic adenocarcinoma signaling |
2 |
2.59E-02 |
RAD51, CCNE1, BIRC5 |
| Hereditary breast cancer signaling |
1.85 |
2.33E-02 |
RAD51, CCNB1, CDC2 |
| Role of BRCA1 in DNA damage response | 1.62 | 3.28E-02 | RAD51, PLK1 |